Bill Detail
An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access)
This enactment amends the Food and Drugs Act to establish a list of therapeutic products pre-approved for special access to allow streamlined access to treatment for patients with serious or life-threatening conditions or where there is an unmet need. It also provides parameters to guide the Minister of Health in issuing letters of authorization for the sale of new drugs for emergency treatment under the Food and Drug Regulations.
This bill, C-265, aims to improve access to essential treatments for Canadians facing serious or life-threatening conditions. It proposes creating a special list of therapeutic products that are pre-approved for "special access." This means that when a patient has an urgent medical need for a drug not readily available in Canada, or for a rare disease, doctors could more easily get them access to specific approved treatments.
This process is intended to be faster and more streamlined than the current system. It gives the Minister of Health clear guidelines for approving these drugs and allows for specific conditions or limitations on their use to ensure patient safety. This could benefit patients with rare diseases, those with conditions lacking standard treatments, and doctors needing emergency options.